Traders Buy Johnson & Johnson (JNJ) on Weakness

Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Tuesday. $350.10 million flowed into the stock on the tick-up and $249.05 million flowed out of the stock on the tick-down, for a money net flow of $101.05 million into the stock. Of all stocks tracked, Johnson & Johnson had the 10th highest net in-flow for the day. Johnson & Johnson traded down ($1.28) for the day and closed at $146.45

A number of research firms recently commented on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, November 16th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, October 14th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $143.97.

The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The firm has a market capitalization of $396.35 billion, a P/E ratio of 20.06, a P/E/G ratio of 2.31 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.46%. Johnson & Johnson’s payout ratio is 49.32%.

In other Johnson & Johnson news, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the sale, the chief executive officer now owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Insiders have sold a total of 349,805 shares of company stock worth $50,593,707 in the last three months. Insiders own 0.22% of the company’s stock.

Hedge funds have recently modified their holdings of the business. HMS Capital Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $427,000. Stevens Capital Management LP bought a new position in shares of Johnson & Johnson in the first quarter worth $15,675,000. Boulegeris Investments Inc. increased its holdings in shares of Johnson & Johnson by 4.4% in the first quarter. Boulegeris Investments Inc. now owns 130,755 shares of the company’s stock worth $16,756,000 after purchasing an additional 5,544 shares during the period. LS Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the first quarter. LS Investment Advisors LLC now owns 84,414 shares of the company’s stock worth $10,818,000 after purchasing an additional 1,221 shares during the period. Finally, Adell Harriman & Carpenter Inc. increased its holdings in shares of Johnson & Johnson by 2.4% in the first quarter. Adell Harriman & Carpenter Inc. now owns 80,236 shares of the company’s stock worth $10,282,000 after purchasing an additional 1,847 shares during the period. 66.06% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/11/21/traders-buy-johnson-johnson-jnj-on-weakness.html.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Analyzing a company’s cash flow statement

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply